Reading RBOT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track RBOT free→Reading RBOT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track RBOT free→QuarterlyIQ Insights · RBOT
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On March 9, 2026, Vicarious Surgical Inc. (the “Company”) issued a press release announcing its results for the fiscal year and fourth fiscal quarter ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 hereto. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subj…
Other Events As previously disclosed, on March 3, 2026, the New York Stock Exchange (the “NYSE”) notified the Company that the NYSE had determined to (A) immediately suspend trading in the Company’s common stock, par value $0.0001 per share (the “Common Stock”), due to a determination that the Company had fallen below the NYSE’s continued listing standard requiring listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least $15,000…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Employment Agreement Amendments On March 4, 2026, Vicarious Surgical Inc. (the “Company”) entered into amendments (the “Employment Agreement Amendments”) to the Executive Employment Agreements (the “Employment Agreements”) between the Company and each of Adams Sachs, the President of the Company, and Sammy Khalifa, the Chief Technology Officer of t…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On March 3, 2026, the New York Stock Exchange (the “NYSE”) notified Vicarious Surgical Inc. (the “Company”) that the NYSE had determined to (A) immediately suspend trading in the Company’s common stock, par value $0.0001 per share (the “Common Stock”), due to a determination that the Company had fallen below the NYSE’s continued listing standard requiring listed companies to maintain an averag…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. CEO Employment Agreement Amendment On February 2, 2026, Vicarious Surgical Inc. (the “Company”) entered into an amendment (the “From Amendment) to the Executive Employment Agreement (the “Employment Agreement”) between the Company and Stephen From, the Chief Executive Officer of the Company. Pursuant to the From Amendment, in the event that Mr. Fro…
Entry Into a Material Definitive Agreement. On December 12, 2025, Vicarious Surgical Inc., a Delaware corporation (the “Company”), entered into an At the Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (the “Sales Agent” or “Wainwright”) providing for the sale by the Company of its shares of Class A common stock, par value $0.0001 per share (the “Common Stock”), from time to time, through the Sales Agent, with certain limitations on the amount of Common Stock t…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On December 15, 2025, the NYSE notified the Company that the NYSE has determined to (a) commence proceedings to delist the Company’s warrants, with thirty warrants exercisable for one share of Common Stock, at an exercise price of $345.00 per share, and listed to trade on the NYSE under the symbol “RBOT.WS” (the “Public Warrants”) and (b) immediately suspend trading in the Public Warrants due…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 1, 2025 (the “Effective Date”), Beverly Huss and Randy Clark each resigned as a member of the Board of Directors (the “Board”) of Vicarious Surgical Inc. (the “Company”), effective as of the Effective Date. Ms. Huss’s and Mr. Clark’s resignations were tendered in connection with a decision by the Board to reduce its size, and did not re…
Results of Operations and Financial Condition. On November 12, 2025, Vicarious Surgical Inc. (the “Company”) issued a press release announcing its results for the third quarter ended September 30, 2025 and providing a business update. A copy of the press release is furnished as Exhibit 99.1 hereto. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exc…
Such disclosure includes, but is not limited to, the fact that the Common Warrants and the Common Warrant Shares are being issued in a private placement transaction and have not been registered under the Securities Act and are instead being offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder.
Entry into a Material Definitive Agreement. Registered Direct Offering and Concurrent Private Placement On October 7, 2025, Vicarious Surgical Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional investor (the “Purchaser”), pursuant to which the Company agreed to issue to the Purchaser (i) in a registered direct offering, 588,300 shares (the “Shares”) of the Company’s Class A common stock, par value $0.0001 per share (the “Common S…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 12, 2025 (the “Effective Date”), Donald Tang resigned as a member of the Board of Directors (the “Board”) of Vicarious Surgical Inc. (the “Company”), effective as of the Effective Date. Mr. Tang’s resignation did not result from any disagreement regarding the Company’s operations, policies or practices. In connection with Mr. Tang’s re…
Results of Operations and Financial Condition. On August 12, 2025, Vicarious Surgical Inc. (the “Company”) issued a press release announcing its results for the second quarter ended June 30, 2025 and providing a business update. A copy of the press release issued on August 12, 2025 is furnished as Exhibit 99.1 hereto. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Chief Executive Officer and Director On July 30, 2025, the Board of Directors (the “Board”) of Vicarious Surgical Inc. (the “Company”) appointed Stephen From as Chief Executive Officer of the Company, effective as of August 7, 2025 (the “Effective Date”). The Board also approved an increase to the size of the Board and the appointmen…
Change in Registrant’s Certifying Accountant. (a) Dismissal of Independent Registered Public Accounting Firm. On July 7, 2025, the Company dismissed Deloitte & Touche LLP (“Deloitte”) as the Company’s independent registered public accounting firm. The dismissal of Deloitte was approved by the audit committee (the “Audit Committee”) of the board of directors (the “Board”) of the Company. Deloitte’s audit report dated March 17, 2025 on the Company’s consolidated financial statements as of and f…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on April 10, 2025, Vicarious Surgical Inc. (the “Company”) received a written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) indicating the Company was no longer in compliance with the NYSE’s continued listing standards set forth in Section 802.01B of the NYSE’s Listed Company Manual (the “Minimum Market Capitalization Standard”) due to the fact tha…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Equity Plan Amendment On June 27, 2025, Vicarious Surgical Inc. (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved an amendment (the “Plan Amendment”) to the Company’s 2021 Equity Incentive Plan (the “2021 Plan”) that includes the following material changes…
Results of Operations and Financial Condition. On May 12, 2025, Vicarious Surgical Inc. (the “Company”) issued a press release announcing its results for the first quarter ended March 31, 2025 and providing a business update. A copy of the press release issued on May 12, 2025 is furnished as Exhibit 99.1 hereto. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as ame…
of Form 8-K and shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act or the Exchange Act regardless of any general incorporation language in such filings. 1 Cautionary Note Regarding Forward Looking Statements This Current Report on Form 8-K includes “forward-looking statements” within the meaning o…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 10, 2025, Vicarious Surgical, Inc. (the “Company”) received a written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) indicating the Company is no longer in compliance with the NYSE’s continued listing standards set forth in Section 802.01B of the NYSE’s Listed Company Manual (the “Minimum Market Capitalization Standard”) due to the fact that the Company’s average…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 18, 2025, Randy Clark resigned as President of Vicarious Surgical Inc. (the “Company”), effective as of April 25, 2025. In addition, the Company’s Board of Directors (the “Board”) has appointed Mr. Clark to the Board, effective as of April 25, 2025, pending customary conflict checks. Mr. Clark will serve for a term to continue until the Co…
Results of Operations and Financial Condition. On March 17, 2025, Vicarious Surgical Inc. (the “Company”) issued a press release announcing its results for the fourth quarter and full year ended December 31, 2024 and providing a business update. A copy of the press release issued on March 17, 2025 is furnished as Exhibit 99.1 hereto. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchan…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Sarah Romano as Chief Financial Officer On March 13, 2025, Vicarious Surgical Inc. (the “Company”) announced that Sarah Romano was appointed by the Board of Directors of the Company (the “Board”) as Chief Financial Officer and Treasurer of the Company, effective April 1, 2025 (the “Appointment Date”). Ms. Romano, age 45, has over two…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 12, 2025, John Mazzola notified the Company that he intends to retire from his position as Chief Operating Officer of Vicarious Surgical Inc. (the “Company”), effective April 1, 2025. A copy of the Company’s press release announcing Mr. Mazzola’s retirement is attached hereto as Exhibit 99.1.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 17, 2025, Vicarious Surgical Inc. (the “Company”) entered into a consulting agreement (the “Consulting Agreement”) with William Kelly in connection with Mr. Kelly’s previously disclosed departure from his role as Chief Financial Officer of the Company. Pursuant to the Consulting Agreement, Mr. Kelly will provide consulting and advisory s…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.